» Articles » PMID: 26277595

Genetic Errors of the Human Caspase Recruitment Domain-B-cell Lymphoma 10-mucosa-associated Lymphoid Tissue Lymphoma-translocation Gene 1 (CBM) Complex: Molecular, Immunologic, and Clinical Heterogeneity

Overview
Date 2015 Aug 17
PMID 26277595
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Three members of the caspase recruitment domain (CARD) family of adaptors (CARD9, CARD10, and CARD11) are known to form heterotrimers with B-cell lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (MALT1). These 3 CARD-BCL10-MALT1 (CBM) complexes activate nuclear factor κB in both the innate and adaptive arms of immunity. Human inherited defects of the 3 components of the CBM complex, including the 2 adaptors CARD9 and CARD11 and the 2 core components BCL10 and MALT1, have recently been reported. Biallelic loss-of-function mutant alleles underlie several different immunologic and clinical phenotypes, which can be assigned to 2 distinct categories. Isolated invasive fungal infections of unclear cellular basis are associated with CARD9 deficiency, whereas a broad range of clinical manifestations, including those characteristic of T- and B-lymphocyte defects, are associated with CARD11, MALT1, and BCL10 deficiencies. Interestingly, human subjects with these mutations have some features in common with the corresponding knockout mice, but other features are different between human subjects and mice. Moreover, germline and somatic gain-of-function mutations of MALT1, BCL10, and CARD11 have also been found in patients with other lymphoproliferative disorders. This broad range of germline and somatic CBM lesions, including loss-of-function and gain-of-function mutations, highlights the contribution of each of the components of the CBM complex to human immunity.

Citing Articles

The role of SARS-CoV-2-mediated NF-κB activation in COVID-19 patients.

Zhou Q, Zhang L, Dong Y, Wang Y, Zhang B, Zhou S Hypertens Res. 2023; 47(2):375-384.

PMID: 37872376 PMC: 10838770. DOI: 10.1038/s41440-023-01460-2.


CARD9 Signaling, Inflammation, and Diseases.

Liu X, Jiang B, Hao H, Liu Z Front Immunol. 2022; 13:880879.

PMID: 35432375 PMC: 9005907. DOI: 10.3389/fimmu.2022.880879.


Clinical and Immunological Features of Human BCL10 Deficiency.

Garcia-Solis B, Van Den Rym A, Perez-Caraballo J, Al-Ayoubi A, AlAzami A, Lorenzo L Front Immunol. 2021; 12:786572.

PMID: 34868072 PMC: 8633570. DOI: 10.3389/fimmu.2021.786572.


CARD9 Expression Pattern, Gene Dosage, and Immunodeficiency Phenotype Revisited.

Goel S, Kuehn H, Chinen J, Niemela J, Stoddard J, Yamanaka D J Clin Immunol. 2021; 42(2):336-349.

PMID: 34791587 PMC: 10108093. DOI: 10.1007/s10875-021-01173-6.


CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.

Israel L, Gluck A, Berger M, Coral M, Ceci M, Unterreiner A Oncogenesis. 2021; 10(4):32.

PMID: 33824280 PMC: 8024357. DOI: 10.1038/s41389-021-00321-2.


References
1.
Casanova J, Abel L . The genetic theory of infectious diseases: a brief history and selected illustrations. Annu Rev Genomics Hum Genet. 2013; 14:215-43. PMC: 4980761. DOI: 10.1146/annurev-genom-091212-153448. View

2.
Xie C, Han Y, Fu L, Li Q, Qiu X, Wang E . Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer. Tumour Biol. 2014; 35(8):7957-64. DOI: 10.1007/s13277-014-2070-2. View

3.
McAllister-Lucas L, Ruland J, Siu K, Jin X, Gu S, Kim D . CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci U S A. 2006; 104(1):139-44. PMC: 1766317. DOI: 10.1073/pnas.0601947103. View

4.
Caruana G . Genetic studies define MAGUK proteins as regulators of epithelial cell polarity. Int J Dev Biol. 2002; 46(4):511-8. View

5.
Fischer K, Tedford K, Wirth T . New roles for Bcl10 in B-cell development and LPS response. Trends Immunol. 2004; 25(3):113-6. DOI: 10.1016/j.it.2003.12.007. View